Regulatory approval
Published by the Health Products Regulatory Authority.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.
This is written in the approval document as:
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Citation
Laboratoires Juvise Pharmaceuticals. Arimidex 1mg Film-coated Tablets (Anastrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf. Revised June 2021. Accessed May 25, 2025.Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Anastrozole | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Anastrozole | |
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Anastrozole |